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Introduction: Untreatable foot problems in diabetics may require lower extremity amputation, which has
a high level of patient mortality. This high mortality rate is worse than most malignancies. The present
study aimed to identify parameters that can be used to estimate survival in DM patients undergoing
below-knee amputations for diabetic foot problems.
Materials and methods: A total of 470 patients (299 males, 171 females) with a mean age of 64.32 years
who underwent below-knee amputation for diabetic foot problems between 2004 and 2014 were
enrolled in the study. The length of time from the operation to time of death was recorded in days.
Patient details were obtained, including age during surgery, BMI, oral antidiabetic and insulin usage,
dialysis therapy history, lower extremity endovascular intervention, previous amputation at the same
extremity, the need for stump revision surgery during follow-up, and above-knee amputation at the
same site. Biochemical test results of pre-operative HbA1c, ESR, and levels of CRP, BUN, and creatinine
were also obtained.
Results: A total of 333 patients (70.9%) died and 137 (29.1%) survived post-surgery. Survival rates were
90% in the first 7 days, 84% in the first 30 days, and 64% after the first year. Patient median life expectancy
post-surgery was 930 ± 106 days. Hemodialysis treatment (p ¼ 0.001), endovascular intervention
(p ¼ 0.04), sex (p ¼ 0.004), age (p ¼ 0.001), BUN level (p ¼ 0.001), and duration of insulin use (p ¼ 0.003)
were shown to be effective predictors of mortality.
Conclusions: Life expectancy is low (<3 years) in DM patients requiring below-knee amputations for
untreatable foot problems. Survival could be predicted by duration of insulin use, age, sex, and renal
insufficiency.
Level of evidence: Level IV, Therapeutic study.
© 2017 Turkish Association of Orthopaedics and Traumatology. Publishing services by Elsevier B.V. This is
an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).Introduction correlated with mortality and lover extremity major amputationsThe diabetic foot syndrome encompasses a number of pathol-
ogies, including diabetic neuropathy, peripheral vascular disease,
Charcot's neuroarthropathy, foot ulceration, osteomyelitis, and the
potentially preventable end point amputation.1 Epidemiological
studies have shown that each year 2.5% of patients with diabetes
are affected by diabetic foot ulcers, and that 15% of patients with
diabetes will ultimately be affected by diabetic foot ulcers.2,3 The
incidence of foot problems ranges from 10% to 25% throughout the
lifetime of a Diabetes mellitus (DM) patient,4 and is stronglyciation of Orthopaedics and
s and Traumatology. Publishing se(LEMAs).5,6
Mortality following amputation ranges from 13 to 40% in 1 year,
35e65% in 3 years, and 39e80% in 5 years, being worse than most
malignancies.7 Therefore, amputation-free survival is important in
assessing the management of diabetic foot problems.
The aim of the present study was to determine parameters that
can be used to estimate survival in DM patients with a planned
below-knee amputation for a diabetic foot problem.
Patients and methods
Patient selection
Retrospective review of prospectively collected data from
Bas¸kent University research and training hospital Orthopaedicrvices by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
S. Beyaz et al. / Acta Orthopaedica et Traumatologica Turcica 51 (2017) 393e397394department database was performed. A total of 1134 patients who
had undergone themajor joint bone amputation between 2004 and
2014 were evaluated. Of the 608 diabetic transtibial amputated
patients who were enrolled with the help of International Classi-
fication of Disease (ICD) codes, 470 were included in the study, the
remainder were excluded for the following criteria's; if they had
disarticulation at or above the knee joint (n ¼ 101), if they were
attending another center for diabetes and for whom inadequate
information was available (n ¼ 25), if they had received a diagnosis
of malignant cancer before the surgery (n ¼ 5), and if they died
from unnatural reasons according to Social Security Institution data
(n ¼ 3; traffic accident, n ¼ 1; firearm injury, n ¼ 1; falling from a
height).
We also obtained the following biochemical data: glycated he-
moglobin (HbA1c) levels, erythrocyte sedimentation rate (ESR), and
C-reactive protein (CRP), blood urea nitrogen (BUN), and creatinine
levels. Patient data acquired were: age during the operation (the
date of the first amputation was used if bilateral amputation was
performed on different dates), history of dialysis therapy, the lower
extremity endovascular intervention procedures, history of previ-
ous amputations at the same extremity, the need for stump revision
surgery during follow-up, and above-knee amputation at the same
site. Body mass index (BMI), DM, and periods of oral antidiabetic
and insulin use were also recorded. Data are presented in Tables 1
and 2.
Statistical analysis
Normally distributed data were analyzed by the ShapiroeWilk
test. The Student's t-test was used to compare two independent
groups of normally distributed variables, while theManneWhitney
U test was used for non-normal data. Pearson's chi-squared test
was used to investigate relationships between categorical variables.
Logistic regression analysis estimated odds ratios and 95% confi-
dence intervals (CIs). Survival probabilities were estimated using
KaplaneMeier curves. Cox regression analysis was performed toTable 1
Results of univariate cox regression method to determine important factor on survival p
Variables Total Total exitus
(n (%))
Exitus male
(n (%))
Exitus fe
(n (%))
Gender 470 333 (70.1) 201 (43) 132 (28)
Male 299 201 (67)
Female 171 132 (77)
Dialysis
þ 336 224 (67) 128 (38) 96 (29)
 134 109 (81) 73 (54) 36 (27)
Revision surgery
þ 115 80 (70) 50 (43) 30 (26)
 355 253 (71) 151 (43) 102 (29)
Periferic arterial disease
þ 74 48 (65) 24 (32) 24 (32)
 396 285 (72) 177 (45) 108 (27)
Embolectomy
þ 24 15 (63) 10 (42) 5 (21)
 446 318 (71) 191 (43) 127 (28)
Angiography
þ 191 126 (66) 71 (37) 55 (29)
 279 207 (74) 130 (47) 77 (28)
Previous amputation surgery 240 94 (39) 61 (25) 33 (14)
Small bone and joint amputation 93 65 (70) 45 (48) 20 (22)
Middle bone and joint amputation 47 29 (62) 16 (34) 13 (28)
Above to knee amputation 132 96 (73) 64 (48) 32 (24)
Side
Right vs bilateral 214 155 (73) 89 (42) 66 (31)
Left vs bilateral 188 120 (64) 71 (38) 49 (26)
Bilateral 56 47 (84) 32 (57) 15 (27)
*Significant at 0.05 level.determine the important factors affecting overall survival proba-
bilities. Statistical analyses were performed using SPSS v22.0
(Chicago, IL, USA). p values < 0.05 were deemed statistically
significant.
Results
A total of 470 patients were enrolled (299 males and 171 fe-
males) in the study. The mean age of the patients was 64.32 years
(range, 20e101 years). The mean age of male patients was 63.21
years (range, 29e88 years), whereas female patients were 66.26
years (range, 20e101 years). One unit of increase in age was asso-
ciated with a 1.034-fold (95%CI, 1.024e1045) increase in mortality.
Following the below-knee amputation, a total of 137 patients
(29.1%) survived, and 333 (70.9%) died (Table 2, Fig. 1). During the
first 7 days post-surgery, the survival rate was 90%; this fell to 84%
in the first 30 days, and to 64% by the end of the first year. The life
expectancy of patients was median 930 ± 106 days. The mean age
of women undergoing below-knee amputation was higher than
that of males (Table 1), and their post-operative lifetime was
significantly (1.38 times) shorter (95% CI, 1.113e1.728, p ¼ 0.040;
Table 2).
The life expectancy of patients undergoing dialysis treatment
was 674 ± 174 days (95% CI, 710e1038), whereas it was 1132 ± 140
days (95%CI, 1276e1628) in patients not receiving dialysis treat-
ment, so hemodialysis was shown to increase mortality by 1.53
times (95% CI,1.218e1.936) (Table 2). Only 96 (72.7%) of women and
128 (63.6%) of men losing their lives were receiving dialysis ther-
apy. Also, one unit of increase in the BUN value was associated with
a 1.009-fold (95%CI, 1.005e1.014) increase in mortality (Table 1).
Patients who underwent preoperative endovascular interven-
tion also had a 1.26-fold higher in mortality than those who did not
(hazards ratio (HR): 1.262, 95% CI, 1.011e1.575, p ¼ 0.040).
Patients had been diagnosed with DM and had received oral
antidiabetic drug (OAD) and insulin therapy for an average of 10
and 7 years, respectively (Table 1). A 1-year increase in the use ofrobabilities.
male Median living
day ± std. error
Mean age during
surgery (minemax)
HR [95%CI] P
64.32 (20e101) 1.38 [1.112e1.728] 0.004*
1171 ± 109.46 63.21 (29e88)
457 ± 153.76 66.32 (20e101)
1.535 [1.218e1.936] 0.001*
674 ± 174.65 61.07 (29e84)
1132 ± 140.09 65.61 (20e101)
1.116 [0.868e1.436] 0.392
1147 ± 141.05 63.68 (20e86)
853 ± 118.07 64.52 (29e101)
1.152 [0.868e1.436] 0.365
1239 ± 311415 67.20 (43e89)
888 ± 105.21 63.78 (20e101)
0.834 [0.496e1.401] 0.492
1567 ± 317.49 71.13 (46e89)
893 ± 104.52 63.95 (20e101)
1.262 [1.011e1.575] 0.040*
1208 ± 116.15 64.72 (32e101)
734 ± 126.95 64.04 (20e90)
1029 ± 155.08 63.51 (31e89) 1.060 [0.834e1.346] 0.634
906 ± 182.61 62.77 (31e89) 1.025 [0.779e1.350] 0.859
1196 ± 312.10 64.98 (40e84) 0.800 [0.545e1.178] 0.260
674 ± 190.66 64.28 (32e88) 1.054 [0.830e1.337] 0.667
906 ± 179.36 65.60 (20e90) 0.837 [0.603e1.161] 0.286
960 ± 160.77 63.40 (36e87) 0.693 [0.494e0.972] 0.034
876 ± 264.44 62.25 (29e101)
Table 2
Results of multivariate cox regression method to determine important factor on survival probabilities.
Variables Median value [minemax] HR [95%CI] P
Age 65 [20e101] 1.034 [1.024e1.045] 0.001*
BMI (kg/m2) 29 [18e49] 1.019 [0.978e1.061] 0.369
HbA1c (%) 8.8 [4.3e15.9] 0.977 [0.920e1.038] 0.448
Sedimentation (mm/h) 95 [8e204] 0.997 [0.993e1.001] 0.151
CRP (mg/L) 128 [3e469] 0.999 [0.998e1.001] 0.451
BUN (mg/dL) 32 [7e144] 1.009 [1.005e1.014] 0.001*
Creatinin (mg) 1.34 [0.26e90] 1.015 [1.000e1.031] 0.051
Oral antidiabetic using time (year) 10 [1e30] 0.972 [0.920e1.026] 0.300
Insulin using time (year) 7 [1e25] 1.109 [1.036e1.188] 0.003*
DM time (year) 18 [3e50] 1.010 [0.992e1.028] 0.273
*Significant at 0.05 level.
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whereas the use of OAD and the duration of DM had no effect on the
mortality rate (Table 1).
It was found that performing revision surgery after a previous
amputation of the same extremity, the inclusion of above-knee
amputation, BMI, duration of diabetes, peripheral arterial disease
(PAD), performing an embolectomy, and ESR, CRP, creatinine, and
HbA1c blood levels had no significant effect on mortality (Tables 1
and 2). Previous small and/or middle joint amputation has no
correlation with above or below knee amputation (Table 2).
Discussion
Against a background of changing treatment options for limb
salvage, we aimed to review the effect this has on mortality rates
for the population who go on to have a transtibial amputation.
The mortality rates reported in this study demonstrated the
frailty of the population, with 16% of people dying within 30-
days. In a similar study, lower rates have been reported in
Scandinavian studies with 19e30% of people dying in the first
month after LEMA,8e10 while in other comparable western pop-
ulations, this is reported to be much lower, around 10%.11,12 It hasFig. 1. Kaplan Meier survival estimates after a first lower knee amputation.been suggested that LEMA in people with vascular disease might
be performed as pain relief at the final stages of care.10 Investi-
gation of underlying influences from health services, surgical
decisions and patient motivations behind decisions to amputate
might help to explain some of the differences in post-operative
mortality rates between studies. As an example, a poorer mor-
tality outcome has been found when there are in-hospital delays
in decision-making because the patients in our immediate region
are mostly unwilling to have amputation surgery and resort to
alternative therapies.
Diabetic nephropathy is the most important cause of renal
insufficiency in both developed and developing countries.13
Moreover, the amputation rate of lower extremities is six times
higher in patients receiving hemodialysis compared with those
who do not,14 and it was also found that the life expectancy of
patients receiving hemodialysis therapy to be 1.5 time shorter than
those not receiving treatment. Previously, mortality rate was 1,56
fold increased with elevated serum levels of BUN (>35 mg/dl),
which supports our current data.15
DM patients have a strong correlation between blood glucose
control and the development of diabetic foot ulcers.16 Hypergly-
cemia is known to interfere with the migration, adhesion, phago-
cytosis, and opsonization of leucocytes.17 When other factors are
eliminated, a 1% elevation in the level of HbA1c is reported to in-
crease the PAD risk by 28% (95% CI, 12e46).18 This same study
showed that when the main causes of death were considered to be
vascular, a shorter lifespan was expected in patients with elevated
HbA1c levels and PAD; however, they reported that neither
parameter contributed to the expected lifespan. Previous studies
reported that patients with HbA1c levels over 7.5% (58 mmol/mol)
had increased amputation rates of 20%e54%.6,19,20 On the other
hand Winskley et al found a relationship between high HbA1c
levels and mortality (HR: 0.73; CI, 0.56e0.96).21 In the present
study, no correlation was observed between HbA1c and mortality.
However, the mean HbA1c value in the study was 8.8% (73 mmol/
mol), which is 17% higher than 7.5% HbA1c value. This condition
was commented on as severe fluctuations in the blood glucose
regulation in the last three months of a patient.
Despite the known relationship between patient mortality and
the occurrence of lower extremity major amputation for diabetic
foot problems, data regarding the effects of amputation level on the
mortality of a patient are limited. In the present study, no signifi-
cant difference was found in mortality of 240 patients who un-
derwent smaller and/or middle bone - joint amputation prior to
below-knee amputation and the 132 patients in whom above-
knee amputation was required. Several studies have investigated
the efficacy of disease duration, regulation of blood glucose level,
HbA1c level, blood levels of BUN, CRP, and ESR, BMI, additional
comorbid diseases (renal insufficiency, congestive heath failure,
and hypertension), smoking, sex, and age on estimating the
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the present study, indicators such as ESR and CRP had no significant
effect on mortality.
Previous studies have shown that patients with high BMI levels
have a high mortality rate. Ilavska et al reported that immunolog-
ical dysfunction is higher in patients with high BMI. This dysfunc-
tion was reported to cause an increase in mortality as a result of
delays in wound healing and being unable to prevent sepsis. In the
same group of patients, it was found that major vascular problems
were higher and contributed to mortality.27
Won et al reported 1-year mortality rates of patient with dia-
betic foot ulcers who did and did not undergo amputation as
34% (n ¼ 114) and 3% (n ¼ 167), respectively.6 Fortington
et al determined life expectancy to be 25 months in patients who
underwent lower extremity major amputations, compared with
20.7 months in patients with non-diabetic vascular disorders
however, this is not statistically meaningful.5 They reported that
22% of patients died during the postoperative 30 days and that 44%
died in the first year after surgery. They found that the patient's age,
location, previous peripheral vascular interventions, and history of
cerebrovascular disease negatively affected early and latemortality,
while renal failure and cardiovascular disorders affected late period
mortality. In the present study, survival rates were 90%, 84%, and
64% in the first 7 days, 30 days, and at the end of first year,
respectively.
In the present study, the number of male patients was higher
than that of female patients. Although some previous studies re-
ported no difference between the occurrence of diabetic foot ulcers
and sex, others state that the diabetes-related amputation rate is
higher in male patients.22,28,29 The reason for the high rate in males
has been suggested to be the negative effects of bad lifestyle habits
such as alcohol consumption and smoking, and poor foot care,
which are worse in men than in women.20,22 So absenteeism is
higher among men, ulcerations will take longer to recover, and
ulcers are more likely to end in amputation.30 These results indi-
cated the potential need for the health care system to devise a
primary care strategy that will help ensure that men with diabetes
receive good care.
PAD was present in approximately half of all patients admitted
to hospital with diabetic foot problems in a previous study.31 The
value of endovascular intervention in recanalization lower ex-
tremity arterial occlusion is currently under debate.32,33 In the
present study, the life expectancy was found to be 60% higher in
patients who had undergone peripheral endovascular intervention
compared with those who had not. The decision to take an endo-
vascular intervention is made by the interventional radiologist.
Considering DM pathology at the cellular level, it was expected
that the disease duration would have an effect on patient survive;
however, this was not the case in the present study. The mean
duration of DM was found to be 18 years. The patients' mean age
was 64,2 years. It was diagnosed during their late 40s.
Previous studies have shown that the compliance with the
treatment of diabetic patients has been steadily decreasing over the
years, While OAD therapy, diet and exercise, a first step in diabetes
treatment, cause fewer fluctuations in blood glucose levels, insulin
therapy led much and higher and more common fluctuations in
patients. We detected that a 1-year increase in the duration of 10-
year OAD and 7-year insulin usage increased mortality by 0.9- and
1.1-fold, respectively. Age was another factor shown to increase
mortality in the study. It was observed that a 1-year increase in age
increased the mortality by 1.034-fold.
Diabetic foot problems are the visible effect of fluctuations in
blood glucose on the all of the body over time. When this causes
complications in the lower extremities, the effects on the cerebral
and cardiac systems are greater, which is the main reason formortality. Additionally, the strong relation between infection and
hyperglycemia decreases the overall survival time.
The present study is the most extensive to date to investigate
patients who underwent below-knee amputations because of dia-
betic foot. It shows the effect of preoperative parameters on patient
life expectancy. Nevertheless, it had a number of limitations. First it
is retrospective. The presence of co-morbid diseases, ASA risk
values given by anesthesia, the duration of dialysis in patients
receiving dialysis therapy, educational status, or the causes of death
during amputation were not investigated. Further studies are
therefore necessary to overcome these limitations.
Conclusion
Untreatable foot problems in diabetic patients that can be
detected early while being indicative of a more serious problem.
The present study shows that life expectancy was less than median
3 years in diabetic patients having clinical findings and requiring
below-knee amputation. Age, sex, and renal insufficiency appear to
be key factors in determining the length of the survival period of
these patients.
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